General

Did This Lung Cancer Treatment Just Outflank Merck’s Keytruda?

Summit shares jumped Monday after positive late-stage indications vs. Merck’s Keytruda. The biotech stock rallied 30%.
Shares:

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *